Research
Read how they describe their research on their Université Laval profile.
Latest funding
- $634,951
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
CIHR · 2023 · Co-investigator
- $374,850
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial
CIHR · 2023 · Co-investigator
No publications available.
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
Principal investigators: Castellucci, Lana
Keywords: Anticoagulation; Bleeding Risk; Venous Thromboembolism
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial
Principal investigators: Carrier, Marc; Kahn, Susan R; Le Gal, Grégoire; Shivakumar, Sudeep P; Siegal, Deborah M
Keywords: Clotting Defects/Thrombosis; Colchicine; Deep Vein Thrombosis; Inflammation; Pilot Study; Post Thrombotic Syndrome; Randomized Controlled Trial; Venous Thromboembolism
From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.